|Up a level|
Heidemann, E. and Stoeger, H. and Souchon, R. and Hirschmann, W.-D. and Bodenstein, H. and Oberhoff, C. and Fischer, J. T. and Schulze, M. and Clemens, M. and Andreesen, Reinhard and Mahlke, M. and König, M. and Scharl, A. and Fehnle, K. and Kaufmann, M. (2002) Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 13 (11), pp. 1717-29.